Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 72,689	$ 41,880
Research and development related success payments and contingent consideration	(55,438)	127,050
General and administrative	14,434	11,821
Total operating expenses	31,685	180,751
Loss from operations	(31,685)	(180,751)
Interest income, net	339	121
Other income (expense), net	(102)	13
Net loss	$ (31,448)	$ (180,617)
Net loss per common share - basic and diluted	$ (0.17)	$ (1.52)
Weighted-average number of common shares - basic and diluted	185,955	119,131